Selecting the Appropriate Patients for Targeted Therapies in Acute Myeloid Leukemia
John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
John DiPersio, MD, PhD, chief of the Division of Oncology and director, Siteman Cancer Center, University of Washington School of Medicine, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibodydrug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
In the current landscape, the available targeted therapies are given to any patient with acute myeloid leukemia (AML), regardless of whether they express what the drug is targeting. This is because the early-stage studies tend to include a broader patient population as the investigators are interested in understanding what occurs when a patient’s expression to the antigen is non-existent, low, or high. This will answer the question of which patients are the appropriate patients for targeted AML therapies. Oncologists are still unsure of this, DiPersio says.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
